[{"content":"","date":"18 November 2021","externalUrl":null,"permalink":"/categories/","section":"Categories","summary":"","title":"Categories","type":"categories"},{"content":"Face-to-Face annual meeting 2021 in Boston, MA.\n","date":"18 November 2021","externalUrl":null,"permalink":"/post/post-6/","section":"Posts","summary":"","title":"GLASS Annual Meeting 2021","type":"post"},{"content":"The Glioma Longitudinal AnalySiS (GLASS) consortium comprising neuropathologists, clinicians, scientists, and bioinformaticians from leading institutions across the globe was inaugurated in 2015, to accelerate efforts to (1) understand glioma tumor evolution and (2) expose therapeutic vulnerabilities.\nGLASS aims to achieve these goals through molecular profiling of tumor specimens obtained at multiple time points along the course of glioma disease, in the context of precise clinical annotation and imaging. Towards that purpose, GLASS has curated a molecular Data Resource that is publicly accessible. The current Data Resource includes multi-timepoint molecular profiles from more than 200 patients with a glioma.\nRead our position paper: The Glioma Longitudinal Analysis Consortium. Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium. Neuro Oncol. 2018 PMID: 29432615.\nPlease use the menu bar (in the header or one of top corners) to navigate through our webpages and learn more.\n","date":"18 November 2021","externalUrl":null,"permalink":"/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Glioma Longitudinal AnalySiS (GLASS) Consortium","type":"page"},{"content":"","date":"18 November 2021","externalUrl":null,"permalink":"/tags/meetings/","section":"Tags","summary":"","title":"Meetings","type":"tags"},{"content":"","date":"18 November 2021","externalUrl":null,"permalink":"/categories/news/","section":"Categories","summary":"","title":"News","type":"categories"},{"content":"","date":"18 November 2021","externalUrl":null,"permalink":"/post/","section":"Posts","summary":"","title":"Posts","type":"post"},{"content":"","date":"18 November 2021","externalUrl":null,"permalink":"/tags/sno/","section":"Tags","summary":"","title":"SNO","type":"tags"},{"content":"","date":"18 November 2021","externalUrl":null,"permalink":"/tags/","section":"Tags","summary":"","title":"Tags","type":"tags"},{"content":"Face-to-Face annual meeting 2019 in Phoenix, AZ.\n","date":"21 November 2019","externalUrl":null,"permalink":"/post/post-5/","section":"Posts","summary":"","title":"GLASS Annual Meeting 2019","type":"post"},{"content":"Face-to-Face annual meeting 2018 in New Orleans, LA.\n","date":"1 October 2018","externalUrl":null,"permalink":"/post/post-4/","section":"Posts","summary":"","title":"GLASS Annual Meeting 2018","type":"post"},{"content":"Face-to-Face annual meeting 2017 in San Francisco, CA.\n","date":"1 October 2017","externalUrl":null,"permalink":"/post/post-3/","section":"Posts","summary":"","title":"GLASS Annual Meeting 2017","type":"post"},{"content":"Face-to-Face annual meeting 2016 in Scottsdale, AZ.\n","date":"1 October 2016","externalUrl":null,"permalink":"/post/post-2/","section":"Posts","summary":"","title":"GLASS Annual Meeting 2016","type":"post"},{"content":"Our first Face-to-Face annual meeting 2015 in San Antonio, TX.\n","date":"1 October 2015","externalUrl":null,"permalink":"/post/post-1/","section":"Posts","summary":"","title":"GLASS Annual Meeting 2015","type":"post"},{"content":"","externalUrl":null,"permalink":"/author/","section":"Authors","summary":"","title":"Authors","type":"author"},{"content":"Please submit inquiries on GLASS to Roel Verhaak\n","externalUrl":null,"permalink":"/contact/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Contact","type":"page"},{"content":"The current GLASS Data Resource was publicly released on May 31, 2022 and is available via http://www.synapse.org/glass. Details on how the Data Resource was compiled and what it includes are available on the Synapse portal, as well as terms of use.\nFAQ # What is included in the GLASS Data Resource? The GLASS Data Resource consists primarily of standardized somatic variants (somatic single-nucleotide variants and DNA copy number segments) and clinical annotation of a cohort of adult patients with a glioma. On a subset of cases, gene expression profiles and/or DNA methylation profiles are available. All profiles were contributed by GLASS members. As a result, the GLASS Data Resource is a heterogeneous dataset. Please take a moment to familiarize yourself with the Resource per the descriptions on the Synapse portal: https://www.synapse.org/glass.\nWhat processing pipelines and tools were used to establish the GLASS Data Resource? All pipelines and descriptions are available on the Verhaak lab Github page.\nCan the raw sequencing data be analyzed? Not at this time. The GLASS Data Resource was compiled from datasets contributed by GLASS members world wide. This means there is a number of jurisdictions that need to be considered for different subsets of the Data Resource. The GLASS Consortium continues to explore options for making analysis of the raw data possible. Suggestions are always welcome. Contact details on the Contact page.\nHow often will the GLASS Data Resource be updated and when is the next release? Future releases of the GLASS Data Resource are in development. While we do not have an anticipated date of release at this time, we are working towards a bi-annual release schedule. Benefits of becoming a GLASS member include early access to the Data Resource. Further information on becoming a member can be found on the Membership page.\nWhat preprocessing pipelines were used to create the GLASS Data Resource? For information on processing pipelines, please review the information on GLASS Synapse Portal, https://www.synapse.org/glass.\n","externalUrl":null,"permalink":"/datasets/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Data Resources","type":"page"},{"content":"Participation in the GLASS consortium is based on availability of paired high-quality tumor samples and/or molecular characterization of such pairs. Sites are actively being recruited and interested parties are encouraged to participate. GLASS was developed according to the principles of The Cancer Genome Atlas (TCGA) with a focus on data availability, open access, and collaborative team science. Benefits of GLASS membership includes early access to the GLASS Data Resource and joining a vibrant community of neuro-oncology researchers.\n","externalUrl":null,"permalink":"/membership/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Membership","type":"page"},{"content":"This website does not ask for or store personal information such as names, email addresses, or telephone numbers.\nWith your consent, we use Google Analytics to see how visitors use the site: first and repeat visits, which pages are read, and how visitors move between pages. We use only summary reports to improve the site. A notice on your first visit lets you accept or reject analytics. Your choice is stored in your browser; clear your browser data to see the notice again.\nThe site is hosted by Netlify. Its login script for content editors stores data only when an editor logs in. Fonts and search run on this site and do not contact other services.\nIf you have questions about this policy, please use the Contact page.\n","externalUrl":null,"permalink":"/privacy-policy/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Privacy Policy","type":"page"},{"content":" Publications from the GLASS Consortium # Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell, 2022. DOI:10.1016/j.cell.2022.04.038\niGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2020. DOI:10.1093/neuonc/noaa160\nLongitudinal molecular trajectories of diffuse glioma patients. Nature, 2019. DOI: 10.1038/s41586-019-1775-1\nCommentary: The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas. Ashwin Narayanan, Sevin Turcan. Cell, 2020. DOI:10.1016/j.cell.2020.01.016.\nGlioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018. DOI:10.1093/neuonc/noy020\nA non-exhaustive list of publications in which GLASS data were used: # Alghamri et al. Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. doi:10.1093/noajnl/vdaa042.\nAnderson et al. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Cold Spring Harb Mol Case Stud. 2020 Feb 3;6(1):a004671. doi: 10.1101/mcs.a004671.\nGromeier et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021 Jan 13;12(1):352. doi:10.1038/s41467-020-20469-6.\nKumthekar et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021 Mar 10;13(584):eabb3945. doi:10.1126/scitranslmed.abb3945.\nGarofano et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021 Feb;2(2):141-156. doi:10.1038/s43018-020-00159-4.\nKocakavuk et al. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genetics. 2021 Feb;2(2):141-156. doi:10.1038/s41588-021-00874-3.\nClaus et al. Environmental and sex-specific molecular signatures of glioma causation. Neuro Oncol. 2021 May 4;noab103. 10.1093/neuonc/noab103.\nWu et al. Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. Br J Cancer. 2021 Jul;125(2):255-264.doi: 10.1038/s41416-021-01418-6.\nLiu et al. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas. Acta Neuropathol Commun. 2022 Mar 9;10(1):32. doi: 10.1186/s40478-022-01339-2.\nWu et al. Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discov. 2022 Sep 19:CD-22-0196. doi: 10.1158/2159-8290.CD-22-0196.\nKashani et al. Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors.Neuro Oncol. 2022 Sep 17:noac220. doi: 10.1093/neuonc/noac220.\nSun S et al. Molecular and clinical characterization of PTRF in glioma via 1,022 samples. BMC Cancer. 2023 Jun 16;23(1):551. doi: 10.1186/s12885-023-11001-2.\nKocakavuk E et al. Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol. 2023 Sep 5;25(9):1721-1723. doi: 10.1093/neuonc/noad095.\nAndrieux G et al. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence. Genome Med. 2023 Jul 11;15(1):48. doi: 10.1186/s13073-023-01207-1.\nJeon HM et al. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer Cell. 2023 Aug 14;41(8):1480-1497.e9. doi: 10.1016/j.ccell.2023.06.007.\nFabro F et al. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. Int. J. Mol. Sci. 2023, 24(21), 15678; https://doi.org/10.3390/ijms242115678.\nMu Q et al. Identifying predictors of glioma evolution from longitudinal sequencing. Sci Transl Med. 2023 Oct 4;15(716):eadh4181. doi: 10.1126/scitranslmed.adh4181.\nRautajoki KJ et al. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. Acta Neuropathol Commun. 2023 Nov 6;11(1):176. doi: 10.1186/s40478-023-01669-9.\nxx\n","externalUrl":null,"permalink":"/publications/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Publications","type":"page"},{"content":"I am a Professor in the Department of Neurosurgery at the Yale School of Medicine. I lead a cancer biology lab with a research focus on 1. Brain tumors and 2. Extrachromosomal oncogene DNA amplification. In particular, we study the process of tumor evolution and therapy resistance. Visit verhaaklab.com for more.\n","externalUrl":null,"permalink":"/author/roel-verhaak/","section":"Authors","summary":"","title":"Roel Verhaak","type":"author"},{"content":"Tumor recurrence presents substantial clinical challenges and is a leading cause of cancer mortality. Comprehensive genomic profiling initiatives have enabled the identification and cataloging of genomic alterations across the primary tumor of all major cancers; however, it is increasingly evident that these tumors are not static entities. Instead, the tumors display spatiotemporal evolution and dynamic heterogeneity whereby divergent clones emerge with distinct genotypes that confer unique selection advantages and facilitate therapy resistance. Meeting the challenges, consequently, demands expansion of cancer characterization initiatives towards longitudinal profiling.\nWhile small cohort assessment has improved our understanding of some cancers including the highly malignant brain tumor glioblastoma (GBM), comprehensive longitudinal assessment of tumor evolution based on cohorts powered to make statistically significant discoveries remains to be performed. Indeed, procuring and analyzing longitudinal samples involves a a number of logistical and scientific challenges. Global collaboration can mitigate these challenges, and collaboration among researchers in the neuro-oncology community particularly has much to offer.\nThe GLASS consortium intends to generate a longitudinal genomic/molecular dataset representing a large cohort of glioma patients across 3 specified diffuse glioma genomic subtypes: IDH-wild-type, IDH-mutant, and IDH-mutant 1p/19q co-deletion. These initiatives have the potential to identify practice-changing new insights and will provide a useful reference dataset to the glioma community.\n","externalUrl":null,"permalink":"/about/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Why GLASS?","type":"page"},{"content":" Steering Committee # Jason Huse, MD Anderson, Houston, TX, USA Roel Verhaak, Yale School of Medicine, New Haven, CT, USA Pieter Wesseling, VU Medical Center, Amsterdam, the Netherlands Committees # Clinical Annotation – Laila Poisson, Henry Ford Health System, Detroit, USA; Mustafa Khasraw, Duke University, Durham, NC DNA Methylation – Houtan Noushmehr, Henry Ford Health System, Detroit, USA Imaging – Spyridon Bakas, Indiana University School of Medicine, Indianapolis, IN Data Infrastructure and Processing – Roel Verhaak, Yale School of Medicine, New Haven, CT, USA Members: # Kenneth Aldape, NIH, Bethesda, MD, USA Kristin D. Alfaro, MD Anderson, Houston, TX, USA Samirkumar B. Amin, Yale School of Medicine, New Haven, CT, USA Kevin J. Anderson, Jackson Laboratory for Genomic Medicine, Farmington, CT, USA David M. Ashley, Duke University, Durham, NC, USA Spyridon Bakas, Indiana University School of Medicine, Indianapolis, IN Pratiti Bandopadhayay, Dana-Farber Cancer Institute, Boston, MA, USA Jill S. Barnholtz-Sloan, National Cancer Institute, Bethesda, DC, USA Floris P. Barthel, TGEn, Phoenix, AZ, USA Rameen Beroukhim, Dana-Farber Cancer Institute, Boston, MA, USA Christoph Bock, CeMM \u0026amp; Medical University of Vienna, Vienna, Austria Priscilla K. Brastianos, Massachusetts General Hospital, Boston, MA, USA Daniel J. Brat, Northwestern, Chicago, IL, USA Andrew R. Brodbelt, University of Liverpool, Liverpool, UK Ketan R. Bulsara, UConn Health, Farmington, CT, USA Aruna Chakrabarty, Leeds University, Leeds, UK Tamrin Chowdhury Yale School of Medicine, New Haven, CT, USA Jeffrey H. Chuang, JAX, Farmington, CT, USA Elizabeth B. Claus, Yale University, New Haven, CT, USA Elizabeth Cochran, Medical College of Wisconsin, Milwaukee, WI, USA Jennifer Connelly, Medical College of Wisconsin, Milwaukee, WI, USA Joseph F. Costello, University of California San Francisco, San Francisco, CA, USA John F. de Groot, University of California San Francisco, San Francisco, CA, USA Gaetano Finocchiaro, Istituto Besta, Milan, Italy Michael N. Fletcher, DKFZ, Heidelberg, Germany Pim J. French, Erasmus University Medical Center, Rotterdam, Netherlands Hui K. Gan, Olivia Newtown-John Cancer Research Institute, Victoria, Australia Mark R. Gilbert, NCI Center for Cancer Research, Washington, DC, USA Peter V. Gould, Laval University, Quebec, Canada Ann-Christine Hau, Luxembourg Institute of Health (LIH), Strassen, Luxembourg, Luxembourg Chaewon Heo Yale School of Medicine, New Haven, CT, USA Christel Herold-Mende, Heidelberg University, Heidelberg, Germany Stephanie Hilz, University of California San Francisco, San Francisco, CA, USA Craig Horbinski, Northwestern University, Chicago, IL, USA Jason Huse, MD Anderson, Houston, TX, USA Antonio Iavarone, University of Miami, Miami, FL, USA Jooho Lee, Yale School of Medicine, New Haven, CT, USA Azzam Ismail, Leeds University, Leeds, UK Michael D. Jenkinson, University of Liverpool, Liverpool, UK Kevin C. Johnson, Yale School of Medicine, New Haven, CT, USA Steven Kalkanis, Henry Ford Health System, Detroit, MI, USA Tina Karabatsou, Salford Royal Hospital, Salford, UK Ho Keung Ng, Chinese University of Hong Kong, Sha Tin, Hong Kong Mustafa Khasraw, Duke University, Durham, NC, USA Hoon Kim, Sungkyunkwan University, Seoul, South Korea Emre Kocakavuk, Yale School of Medicine, New Haven, CT, USA Mathilde C.M. Kouwenhoven, Amsterdam University Medical Center, Amsterdam, Netherlands Peter S. LaViolette, Medical College of Wisconsin, Milwaukee, WI, USA Peter Lichter, DKFZ, Heidelberg, Germany Keith L. Ligon, Dana-Farber Cancer Institute, Boston, MA, USA Allison K. Lowman, Medical College of Wisconsin, Milwaukee, WI, USA Tathiane M. Malta, University of São Paulo, São Paulo, Brazil Hrvoje Miletic, University of Bergen, Bergen, Norway Annette M. Molinaro, University of California San Francisco, San Francisco, CA, USA Jasmin Mueller, DFKZ, Heidelberg, Germany Do-Hyun Nam, Samsung Medical Center, Seoul, South Korea MacLean Nasrallah, University of Pennsylvania, Philadelphia, PA, USA Simone Niclou, Luxembourg Institute of Health (LIH), Strassen, Luxembourg, Luxembourg Johanna M. Niers, VU Medical Center, Amsterdam, Netherlands Houtan Noushmehr, Henry Ford Health System, Detroit, MI, USA Chul-Kee Park, Seoul National University College of Medicine, Seoul, South Korea Laila M. Poisson, Henry Ford Health System, Detroit, MI, USA Raul Rabadan, CUMC, New York, NY, USA Bernhard Radlwimmer, DFKZ, Heidelberg, Germany Ganesh Rao, Baylor School of Medicine, Houston, TX, USA Guido Reifenberger, University Dusseldorf, Dusseldorf, Germany Federico Roncaroli, University of Manchester, Manchester, UK D. Ryan Ormond, University of Colorado School of Medicine, Aurora, CO, USA Erica Shen, Yale School of Medicine, New Haven, CT, USA Susan C. Short, Leeds University, Leeds, UK Peter A. Sillevis Smitt, Erasmus University Medical Center, Rotterdam, Netherlands Andrew E. Sloan, UH Cleveland Medical Center, Cleveland, OH, USA Ivan Smirnov, University of California San Francisco, San Francisco, CA, USA Marion Smits, Erasmus University Medical Center, Rotterdam, Netherlands Lucy F. Stead, Leeds University, Leeds, UK Erik P. Sulman, NYU Langone Health, New York, NY, USA Hiromichi Suzuki, Tokyo University, Tokyo, Japan Ghazaleh Tabatabai, U Tuebingen, Tuebingen, Germany Georgette Tanner, Leeds University, Leeds, UK Mircea Tesileanu, Yale School of Medicine, New Haven, CT, USA Erwin G. Van Meir, University of Alabama Birmingham, Atlanta, GE, USA Frederick S. Varn, Jackson Laboratory for Genomic Medicine, Farmington, CT, USA Roel G.W. Verhaak, Yale School of Medicine, New Haven, CT, USA Colin Watts, University of Birmingham, Birmingham, UK Michael Weller, University of Zurich, Zurich, Switzerland Pieter Wesseling, Amsterdam Medical Center, Amsterdam, Netherlands Bart A. Westerman, VU Medical Center, Amsterdam, Netherlands Helen Wheeler, U Sydney, Sydney, Australia Adelheid Woehrer, Medical University of Vienna, Vienna, Austria W.K. Alfred Yung, MD Anderson, Houston, TX, USA Gelareh Zadeh, U Toronto, Toronto, Canada Michael Zhang, University of California San Francisco, San Francisco, CA, USA This page may not reflect members currently working in the GLASS working group(s). Please notify Roel Verhaak if you like your name to be listed on this page.\n","externalUrl":null,"permalink":"/working-groups/","section":"Glioma Longitudinal AnalySiS (GLASS) Consortium","summary":"","title":"Working Groups","type":"page"}]